

PATENT 3 89188.0040 13

HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Paul C. Denny et al.

Serial No: 09/929,293

Filed:

August 14, 2001

For:

SALIVA-BASED METHODS FOR

PREVENTING AND ASSESSING

THE RISK OF DISEASES

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

MAIL STOP IDS Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450 Art Unit: 1641

Examiner: Lisa V. Cook

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents Washington D.C. 20231, on

June 3, 2003 Date of Deposit

Name Name Signature

JUN 2 7 2003

TECH CENTER 1600/2900

Dear Sirs:

- The information disclosure statement submitted herewith is being filed within three months of the filing date of the application other than a continued prosecution application, or within three months of the date of entry into the national stage of an international application, or before the mailing date of a first Office Action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under §1.114, whichever event occurs last. 37 C.F.R. §1.97(b).
- 2. The information disclosure statement transmitted herewith is being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113, or a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, whichever occurs first. A statement specified in §1.97(e) or a fee set forth in §1.17(p) is included. 37 C.F.R. §1.97(c).

§1.97(e) STATEMENT

- I, the person signing below, state:
- that each item of information contained in the information disclosure statement was first cited in the attached communication from a foreign patent office in a counterpart foreign application and that the communication is dated not more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(1).

OR

	that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(2).
	OR FEE
	Attached is a fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$180.00). [OR:] Please charge the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00) to Deposit Account No. 50-1314. A copy of this petition is enclosed.
3. 🗌	The information disclosure statement transmitted herewith is being filed after the period specified in §1.97(c), but before, or simultaneously with the payment of the issue fee. A statement specified in §1.97(e) and a fee set forth in §1.17(p) are included. 37 C.F.R. §1.97(d).
	§1.97(e) STATEMENT
	I, the person signing below, state:
	that each item of information contained in the information disclosure statement was first cited in the attached communication from a foreign patent office in a counterpart foreign application and that the communication is dated not more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(1).
	OR
	that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(2).

AND FEE

		Attached is a fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(d). (\$180.00).
4.		If it should be determined that for any reason either an insufficient fee or an excessive has been paid, please charge any insufficiency or credit any overpayment necessary to ensure consideration of the information disclosure statement for the above-identified application to Deposit Account No. 50-1314. A copy of this petition is enclosed.
5 .	\boxtimes	A list of 5 reference(s) is in the enclosed Form PTO-1449.
		NON-ENGLISH LANGUAGE REFERENCES
	\boxtimes	Enclosed is a search report for a counterpart application. The search report Examiner has provided comments on the relevancy of any references cited in the search report.
		The specification incorporates comments on the relevancy of Non-English language references.
		Set forth below are comments provided by the applicant's home country counsel on the relevancy of non-English language references:

Respectfully submitted, HOGAN & HARTSON L.L.P.

> William E. Thomson, Esq. Registration No. 20,719 Attorney for Applicant(s)

Date: June 23, 2003

Biltmore Tower 500 South Grand Avenue, Suite 1900

Los Angeles, CA 90071

Telephone: (213) 337-6700

Facsimile:

(213) 337-6701

FORM PTO-1449

JUN 2 6 2003

INFORMATION DISCOSSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Dock t Numb r (Optional) 89188.0040

August 14, 2001

Applicati n Number 09/929,293

Applicant

Paul C. Denny et al.

Filing Dat

Gr up Art Unit

1641

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DA			
	5,510,122	4/23/1996	Sreebny et al.	424	537				
	4,444,879	4/24/1984	Foster et al.	435	7				
			·						
			-		_				
		ORFIGN PA	 TENT DOCUMEN	ITS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	1	Translation		
	DOGGINENT NOMBER		000,1111	02/100	CODULAGO	YES	NO		
		<u> </u>							
				-					
	OTHER DOCUME	NTS (Including	Author. Title. Date. Pe	rtinent Pages	. Etc.)		-		
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Troxler, T.F. et al. "Molecular Characterization of a Major Weight Mucin from Human Sublingual Gland." Glycobiology. 1997, Vol.7, No. 7, pages 965-973								
	Oemrawshingh I. et al., "Isolation, Purification and Chemical Characterization of Mucins from Human Submandibular Glands. Archives of Oral Biology, 1974, Vol.19, pages 615-626								
Н	Ho, Jenny et al. "Expression of CA19-9, DU-PAN-2, and SPan-1 Antigens on Two Types of Normal Salivary Mucins," Oncology Research. 1993, Vol.5, No. 9, pages 347-356, Abstract only.								

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.